Tags: SOCMA Member News
In recognition of their tireless work during an incredibly challenging year, Pilot Chemical Corp. is awarding bonuses to each of its 400-plus employees at all operations in the U.S. and Mexico.
January 25, 2021
STREM Chemicals, Inc. has licensed a technology based on recent developments in the field of Ni(0) (pre)catalysts from the Max-Planck-Institut für Kohlenforschung respectively the associated Studiengesellschaft Kohle mbH.
January 13, 2021
Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.
January 12, 2021
Aramco and Baker Hughes (NYSE:BKR) have announced the formation of Novel, a 50/50 Joint Venture (JV) to develop and commercialize a broad range of non-metallic products for multiple applications in the energy sector.
December 8, 2020
Sun Chemical has further enhanced its online troubleshooting guide (http://inktsa.sunchemical.com) by adding potential solutions to common pressroom challenges in coldset and metal package printing processes.
December 3, 2020
Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp (CH) site.
December 2, 2020
SOCMA member Lonza congratulates Moderna on interim Phase 3 clinical trial data.
November 16, 2020
ChemDesign is pleased to announce the completion of its new technology center. This facility was developed and built by Keller Inc., with construction completed in the fall of 2020. The 25,000 sq. ft. facility houses multiple functional areas and will serve as the centerpiece and communication hub for the company.
November 12, 2020
Pierre-Alain Ruffieux today joins Lonza Group in the role of Chief Executive Officer. Albert Baehny has taken the role of CEO ad interim since November 2019. He will now work with Pierre-Alain to ensure a smooth handover of leadership before returning to his role as Chairman of the Board of Directors.
November 2, 2020
Lonza announced today that the company has signed
an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.
October 30, 2020
